Process Development and Optimization of Linagliptin Aided by the Design of Experiments (DoE)-Reference-Cited by-同舟云学术

Process Development and Optimization of Linagliptin Aided by the Design of Experiments (DoE)

Published:2022-11-16 Issue:12 Volume:26 Page:3254-3264
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Wang Hailong¹²³,Chen Kai¹^ORCID,Lin Biyue²³,Kou Jingping³,Li Lijun³,Wu Shuming²³,Liao Shouzhu²³,Sun Guodong²³^ORCID,Pu Junwen³,Yang Hua¹^ORCID,Wang Zhongqing²⁴³^ORCID

Affiliation:

1. College of Chemistry and Chemical Engineering, Central South University, Changsha 410083, P. R. China

2. State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871, P. R. China

3. HEC Research and Development Center, HEC Pharm Group, Dongguan 523871, P. R. China

4. School of Pharmacy, Xiangnan University, Chenzhou 423000, Hunan, P. R. China

Funder

Guangdong Science and Technology Department

State Key Laboratory of Anti-Infective Drug Development

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.2c00230

Reference31 articles.

1. 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

2. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors

3. DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment

4. aDong, W.; Huang, Y.; Su, S.; Sun, Y.; Zhang, P. Process for The Preparation of a Xanthine-based Compound. PCT Patent WO2016207364, 2016.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expedited Synthesis of Metal Phosphides Maximizes Dispersion, Air Stability, and Catalytic Performance in Selective Hydrogenation;Angewandte Chemie International Edition;2024-07-03

2. Expedited Synthesis of Metal Phosphides Maximizes Dispersion, Air Stability, and Catalytic Performance in Selective Hydrogenation;Angewandte Chemie;2024-07-03

3. Olaparib Process Development Employing Quality by Design (QbD) Principles;ACS Omega;2024-07-01

4. Efficient Process Development of Abiraterone Acetate by Employing Design of Experiments;ACS Omega;2024-06-24

5. Optimization of Welding Process of Geomembranes in Biodigesters Using Design of Factorial Experiments;Energies;2023-09-13